<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01256801</url>
  </required_header>
  <id_info>
    <org_study_id>GMPE</org_study_id>
    <nct_id>NCT01256801</nct_id>
  </id_info>
  <brief_title>Gene Expression Profiling of Breast Cancer Cells Predict the Response of Malignant Pleural Effusion</brief_title>
  <acronym>GMPE</acronym>
  <official_title>Gene Expression Profiling of Breast Cancer Cells in Pleural Effusion Prodict the Response of Malignant Pleural Effusion to Immunotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing Cancer Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators want to develop a gene expression profile for the prediction of
      immunotherapy response of patients with metastatic breast cancer presenting malignant pleural
      effusion.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. The patiets with malignant pleural effusion are randomizned to be treated with
           cytokins(inteleukin 2) or dendritic cells(DC) plus cytokine induced killer cells(CIK)
           locally.

        2. Malignant pleural effusion from metastatic breast cancer patient is obtained through
           thoracentesis and is centrifugalized to enrich cancer cells before the therapy.

        3. The enriched cancer cells are flash frozen and stored at -80℃ until processing.

        4. The gene expression in pleural effusion is detected by microarray to screen gene markers
           that are differently expressed between groups .

        5. Statistical analysis is performed using unsupervised hierarchical cluster.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2010</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">January 2013</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>immunotherapy response</measure>
    <time_frame>1 month</time_frame>
    <description>Response of malignant pleural effusion to immunotherapy is evaluated with WHO guidelines</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>immunological status</measure>
    <time_frame>1 month</time_frame>
    <description>compare the immunological status of pleural effusion before and after the therapy</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">36</enrollment>
  <condition>Breast Neoplasms</condition>
  <condition>Neoplasm Metastasis</condition>
  <condition>Gene Expression Profiling</condition>
  <condition>Immunotherapy</condition>
  <arm_group>
    <arm_group_label>cytokine</arm_group_label>
    <description>The patients are randomized to receive the cytokine infusion in the pleural cavity</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>cytokine</intervention_name>
    <description>interleukin 2 2 million unit every week</description>
    <arm_group_label>cytokine</arm_group_label>
    <other_name>interleukin 2 2 million unit every week</other_name>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      The cancer cells are taken from the malignant pleural effusion of breast cancer patiets.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        The breast cancer patiets present with pleural effusion and can receive chemotherapy.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients should be histologically confirmed with metastatic breast cancer and
             malignant pleural effusion

          -  an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2;

          -  At least one measurable lesion;

          -  Normal cardiac, hepatic, renal and bone marrow functions;

          -  Life expectancy ≥3 months;

          -  Discontinuity of previous chemotherapy for a minimum of 4 weeks.

          -  Not receive chemotherapy in pleural cavity

        Exclusion Criteria:

          -  previous history of other malignancies;

          -  previous surgery history on the needle biopsy organ;

          -  Serious or uncontrolled concurrent medical illness.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>JUN REN, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Beijing Cancer Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Beijing Cancer Hospital</name>
      <address>
        <city>Beijing</city>
        <zip>100142</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 1, 2010</study_first_submitted>
  <study_first_submitted_qc>December 8, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 9, 2010</study_first_posted>
  <last_update_submitted>July 27, 2015</last_update_submitted>
  <last_update_submitted_qc>July 27, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 29, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beijing Cancer Hospital</investigator_affiliation>
    <investigator_full_name>Jun Ren</investigator_full_name>
    <investigator_title>Director</investigator_title>
  </responsible_party>
  <keyword>Metastatic Breast Neoplasms</keyword>
  <keyword>Gene Expression Profiling</keyword>
  <keyword>immunotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Pleural Effusion</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Pleural Effusion, Malignant</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interleukin-2</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

